知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

33 records (took 0.023 seconds)

    Bicyclic and tricyclic derivatives as thrombin receptor antagonists
    2.
    发明授权
    Bicyclic and tricyclic derivatives as thrombin receptor antagonists 有权
    双环和三环衍生物作为凝血酶受体拮抗剂

    公开(公告)号：US08153664B2

    公开(公告)日：2012-04-10

    申请号：US11865793

    申请日：2007-10-02

    Applicant: Samuel Chackalamannil ,  Mariappan V. Chelliah ,  Yuguang Wang ,  Yan Xia

    Inventor： Samuel Chackalamannil ,  Mariappan V. Chelliah ,  Yuguang Wang ,  Yan Xia

    IPC: C07D401/06 ,  A61K31/4439 ,  A61P7/02 ,  A61P7/12 ,  A61P9/10 ,  A61P29/00 ,  A61P19/02 ,  A61P3/10 ,  A61P3/14 ,  A61P11/06 ,  A61P11/08

    CPC classification number: C07D401/06 ,  C07D417/06

    Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    Abstract translation: 所述式的杂环取代三环或所述化合物，异构体或外消旋混合物的药学上可接受的盐或溶剂合物，其中代表任选的双键，虚线任选是键或无键，导致双键或单键， 如价格要求所允许的，其中E，A，GM，Het，B，X，R 3，R 10，R 11，R 32和R 33在本文中定义，其余取代基如说明书中所定义，以及药物 含有它们的组合物和通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病的方法。 还要求与其它心血管药物联合治疗。

    Oxazoloisoquinoline derivatives as thrombin receptor antagonists
    3.
    发明授权
    Oxazoloisoquinoline derivatives as thrombin receptor antagonists 有权
    恶唑啉异喹啉衍生物作为凝血酶受体拮抗剂

    公开(公告)号：US07888369B2

    公开(公告)日：2011-02-15

    申请号：US11642170

    申请日：2006-12-20

    Applicant: Samuel Chackalamannil ,  Yuguang Wang

    Inventor： Samuel Chackalamannil ,  Yuguang Wang

    IPC: C07D491/14 ,  A61K31/4355 ,  A61P7/02 ,  A61P9/10 ,  A61P9/12 ,  A61P9/06 ,  A61P9/00 ,  A61P9/02

    CPC classification number: C07D487/04 ,  C07D471/04

    Abstract: This application provides for oxazolisoquinoline derivatives of the formula or a pharmaceutically acceptable salt of said compound wherein: B is —CH═CH—; M is —C(R1)(R2)—; and the remaining substituents are as defined in the specification as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. This application also provides for combination therapy with the compounds of Ib or pharmaceutically acceptable salts thereof with other cardiovascular agents.

    Abstract translation: 本申请提供了下式的恶唑啉喹啉衍生物或所述化合物的药学上可接受的盐，其中：B是-CH = CH-; M是-C（R 1）（R 2） - ; 并且其余的取代基如本说明书中所定义，以及含有它们的药物组合物以及通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病的方法。 本申请还提供了将Ib化合物或其药学上可接受的盐与其它心血管药物组合治疗。

    Thrombin receptor antagonists
    5.
    发明授权
    Thrombin receptor antagonists 有权
    凝血酶受体拮抗剂

    公开(公告)号：US07713999B2

    公开(公告)日：2010-05-11

    申请号：US11733635

    申请日：2007-04-10

    Applicant: Samuel Chackalamannil ,  Martin C. Clasby ,  William J. Greenlee ,  Yuguang Wang ,  Yan Xia ,  Enrico P. Veltri ,  Mariappan V. Chelliah

    Inventor： Samuel Chackalamannil ,  Martin C. Clasby ,  William J. Greenlee ,  Yuguang Wang ,  Yan Xia ,  Enrico P. Veltri ,  Mariappan V. Chelliah

    IPC: A61K31/443 ,  C07D307/78

    CPC classification number: C07D405/06 ,  C07D405/14 ,  C07D417/14

    Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond;  represents an optional double bond, n is 0-2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, —OH, (C1-C6)alkoxy, R27-aryl(C1-C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    Abstract translation: 具有下式的杂环取代的三环或其药学上可接受的盐，其中：虚线表示任选的单键; 表示可选的双键，n为0-2; Q是环烷基，任选被R 13和R 14取代; R 13和R 14独立地选自（C 1 -C 6）烷基，（C 3 -C 8）环烷基，-OH，（C 1 -C 6）烷氧基，R 27 - 芳基（C 1 -C 6）烷基，杂芳基，杂芳基烷基，杂环基，杂环基烷基，卤素 和卤代烷基; 或R 13和R 14一起形成3-6个原子的螺环或异环环，Het是单或双环任选取代的杂芳基; 和B是键，亚烷基或任选取代的亚烯基或亚炔基，其中剩余的取代基如说明书中所定义，以及含有它们的药物组合物和治疗与血栓形成，动脉粥样硬化，再狭窄有关的疾病的方法， 高血压，心绞痛，心律失常，心力衰竭和癌症。 还要求与其它心血管药物联合治疗。

    CANNABINOID RECEPTOR MODULATORS
    6.
    发明申请
    CANNABINOID RECEPTOR MODULATORS 审中-公开
    CANNABINOID受体调节剂

    公开(公告)号：US20070254952A1

    公开(公告)日：2007-11-01

    申请号：US11736722

    申请日：2007-04-18

    Applicant: Yuguang Wang ,  Samuel Chackalamannil ,  Yuriko Root

    Inventor： Yuguang Wang ,  Samuel Chackalamannil ,  Yuriko Root

    IPC: A61K31/277 ,  A61K31/138 ,  A61K31/075

    CPC classification number: A61K31/03 ,  A61K31/10 ,  C07C43/225 ,  C07C255/54 ,  C07C255/58 ,  C07C2601/08

    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable salts or solvates thereof, wherein: Ar1 is a chlorophenyl group, Ar2 is a dichlorophenyl group, R1 is a —(CH2)m—X—(CH2)n—R2 group, X is a —NH—, —O—, —C(O)— or —S(O)2— group, and R2 is a substituted phenyl group. These compounds are CB1 receptor modulators. Also disclosed are methods of treating CB1 modulated diseases or conditions such as the metabolic syndrome.

    Abstract translation: 公开了下式的化合物或其药学上可接受的盐或溶剂化物，其中：Ar 1是氯苯基，Ar 2是二氯苯基， 1是 - （CH 2 CH 2）m -X-（CH 2）n - R 2基团，X是-NH-，-O-，-C（O） - 或-S（O）2 - ， - 2是取代的苯基。 这些化合物是CB1受体调节剂。 还公开了治疗CB1调节的疾病或诸如代谢综合征的病症的方法。

    Computer finger mouse
    8.
    发明申请
    Computer finger mouse 审中-公开
    电脑手指鼠标

    公开(公告)号：US20060007152A1

    公开(公告)日：2006-01-12

    申请号：US11172761

    申请日：2005-07-02

    Applicant: Yuguang Wang

    Inventor： Yuguang Wang

    IPC: G09G5/08

    CPC classification number: G06F3/03543 ,  G06F2203/0333

    Abstract: A computer finger mouse includes a concave structure for embrace the fingertips of a hand in a relaxed positions. The concave structure allows the mouse be held and manipulated by the fingertips of a hand only. A hand holding and manipulating the computer finger mouse is in a naturally relaxed and curled position, without requiring static twisting of the hand, wrist, or forearm. As a result, fatigue, discomfort, and pain are minimized or eliminated even after a long period of continuous use.

    Abstract translation: 计算机手指鼠标包括凹形结构，用于在轻松的位置包围手的指尖。 凹形结构允许鼠标被手的指尖保持和操纵。 握住和操纵计算机手指鼠标的手处于自然松弛和卷曲的位置，而不需要手，手腕或前臂的静态扭转。 结果，即使在长时间的连续使用之后，疲劳，不适和疼痛也被最小化或消除。

Patent Agency Ranking